The overall infection rate was not reported in MEASURE-3 and MEASURE-4, and the number of infectious diseases (including those of the ear, upper respiratory tract, and urinary tract infection and Candida infection) in patients treated with IL-17 inhibitors seemed to be more than that in those treated with a placebo, although statistical significance was not reached in these two trials. The gene discussed is IL17A; the disease is urinary tract infection.